TY  - GEN
AU  - Stewart, Stefan
AU  - Seco-Meseguer, Enrique
AU  - Diago-Sempere, Elena
AU  - Marín-Candón, Alicia
AU  - Carmona, Montserrat
AU  - Estébanez, Miriam
AU  - López-Fernández, Luis A
AU  - Imaz-Iglesia, Iñaki
AU  - Del Mar García Saiz, María
AU  - Laserna-Mendieta, Emilio J
AU  - Peiró, Ana M
AU  - Farré, Magí
AU  - Rodriguez-Jimenez, Consuelo
AU  - Saiz-Rodriguez, Miriam
AU  - Sanabria-Cabrera, Judith
AU  - Rosas-Alonso, Rocío
AU  - Abad-Santos, Francisco
AU  - Pedrosa-Pérez, Lucía
AU  - Carcas, Antonio J
AU  - García García, Irene
AU  - Borobia, Alberto M
AU  - iPHARMGx study group
PY  - 2024
DO  - 10.1136/bmjopen-2024-089823
UR  - https://hdl.handle.net/20.500.12105/26625
AB  - Introduction: Genetic variations impact drug response, driving the need for personalised medicine through pre-emptive pharmacogenetic testing. However, the adoption of pre-emptive pharmacogenetic testing for commonly prescribed drugs, such as statins,...
LA  - eng
PB  - BMJ Publishing Group
KW  - Clinical-Pharmacology
KW  - Clinical Trial
KW  - Genetics
KW  - Lipid disorders
KW  - Public health
KW  - Adaptive Clinical Trials as Topic
KW  - Cardiovascular Diseases
KW  - Clinical Trials, Phase IV as Topic
KW  - Cost-Benefit Analysis
KW  - Genotype
KW  - Humans
KW  - Hydroxymethylglutaryl-CoA Reductase Inhibitors
KW  - Pharmacogenomic Testing
KW  - Precision Medicine
KW  - Randomized Controlled Trials as Topic
KW  - Spain
TI  - Phase IV adaptive randomised clinical trials evaluating efficacy and cost-efficacy of pre-emptive pharmacogenetic genotyping strategies in the Spanish National Health System: iPHARMGx Master Protocol and PREVESTATGx nested clinical trial
TY  - research article
ER  -